IDH突变及其抑制剂在恶性肿瘤治疗中的研究进展  

Development of IDH Mutation and Its Inhibitors in Malignant Tumor Therapy

作　　者：赵超然 宋昕樾 于兆进[1] 于丽凤[1] 赵琳[1] 魏敏杰[1] ZHAO Chaoran;SONG Xinyue;YU Zhaojin;YU Lifeng;ZHAO Lin;WEI Minjie(Department of Pharmacology,College of Pharmacy,China Medical University,Liaoning Key Laboratory of Molecular TargetedAnti-tumor Drug Development and Evaluation,Shenyang,Liaoning,110122,China)

机构地区：[1]中国医科大学药学院药理教研室,辽宁省分子靶向抗肿瘤药物药理学研究与评价重点实验室,辽宁沈阳110001

出　　处：《肿瘤药学》2018年第5期657-661,674,共6页Anti-Tumor Pharmacy

摘　　要：异柠檬酸脱氢酶(IDH)是一类参与细胞有氧代谢三羧酸循环的酶家族,IDH家族的突变与很多肿瘤的发生有关,因此IDH成为抗肿瘤治疗的新靶点。目前已发现多种针对IDH突变的抑制剂,并取得了一定的成果,本文对IDH突变及其小分子抑制剂的研究进展进行简要综述。Isocitrate dehydrogenase(IDH)is a group of enzymes involved in cell aerobic metabolism of the tricarboxylic acid cycle.The previous studies have found that the IDH family mutation is associated with the occurrence of many tumors.Therefore,IDH has become the target of novel anti-tumor therapy.Several inhibitors have been found for IDH mutation,and some results have been obtained.In this paper,the research progress of small molecule inhibitors of IDH mutation is reviewed.

关 键 词：IDH家族 抑制剂 恶性肿瘤 

分 类 号：R96[医药卫生—药理学]